www.nature.com/emi

ORIGINAL ARTICLE

Integrated whole-genome sequencing and temporospatial analysis of a continuing Group A *Streptococcus* epidemic

Nahuel Fittipaldi^{1,*}, Gregory J Tyrrell², Donald E Low³, Irene Martin⁴, David Lin⁵, Kumar L Hari⁵ and James M Musser¹

Analysis of microbial epidemics has been revolutionized by whole-genome sequencing. We recently sequenced the genomes of 601 type *emm59* Group A *Streptococcus* (GAS) organisms responsible for an ongoing epidemic of invasive infections in Canada and some of the United States. The epidemic has been caused by the emergence of a genetically distinct, hypervirulent clone that has genetically diversified. The ease of obtaining genomic data contrasts with the relatively difficult task of translating them into insightful epidemiological information. Here, we sequenced the genomes of 90 additional invasive Canadian *emm59* GAS organisms, including 80 isolated recently in 2010–2011. We used an improved bioinformatics pipeline designed to rapidly process and analyze whole-genome data and integrate strain metadata. We discovered that *emm59* GAS organisms are undergoing continued multiclonal evolutionary expansion. Previously identified geographic patterns of strain dissemination are being diluted as mixing of subclones over time and space occurs. Our integrated data analysis strategy permits prompt and accurate mapping of the dissemination of bacterial organisms in an epidemic wave, permitting rapid generation of hypotheses that inform public health and virulence studies. *Emerging Microbes and Infections* (2013) **2**, e13; doi:10.1038/emi.2013.13; published online 27 March 2013

Keywords: bacterial epidemics; Canada; group A Streptococcus; invasive disease; United States; whole-genome sequencing

INTRODUCTION

The recent unparalleled discriminatory power afforded by wholegenome sequencing has proven decisive for understanding aspects of bacterial outbreaks, including cholera,^{1,2} tuberculosis,³ *Listeria monocytogenes*,⁴ *Escherichia coli* O104^{5,6} and Group A *Streptococcus* (GAS also known as *streptococcus pyogenes*).^{7–9} Decreasing costs, enhanced data output and improved protocols now make this technology the method of choice for some aspects of public health microbiology.^{10–12} The ease of obtaining genome data permits the study of the evolutionary events contributing to bacterial clone emergence, strain differentiation, and epidemics at the full-chromosomal level in large samples.¹³ Toward this end, we have used whole-genome sequencing of GAS as a model to understand the fine-structure and molecular architecture of epidemics occurring over many years.^{7,8}

GAS is a human-specific pathogen that causes diseases ranging in severity from uncomplicated pharyngitis to life-threatening necrotizing fasciitis.¹⁴ GAS strains are classified based on the aminoterminal sequence of the M protein, a polymorphic cell-surface adhesin and anti-phagocytic factor encoded by the *emm* gene.^{15–17} Previously, we have used deep-genome sequencing data for 95 *emm3* GAS strains integrated with epidemiological information to resolve the key molecular features of three successive epidemics caused by *emm3* GAS in Ontario, Canada, over a period of 16 years.⁷ This comparative pathogenomic analysis delineated the fine-structure molecular population genetics of these epidemics and defined relationships among the invasive strains responsible for the three epidemics.

More recently, using animal infection models and whole-genome sequencing of 601 emm59 GAS strains, we unambiguously demonstrated that a recently emerged, hypervirulent clone was responsible for a large epidemic of invasive GAS disease that began in 2006 in Western Canada and caused more than 500 invasive cases in 4 years. The epidemic wave extended rapidly to 11 Canadian provinces and territories and to three of the United States.^{8,18} The epidemic clone was distantly related to historic emm59 GAS strains, and also differed from emm59 GAS organisms isolated in other countries.^{8,19} Our genomic investigation precisely informed us about the population genomic landscape of the emm59 GAS epidemic, and permitted us to delineate patterns of geographic dissemination of strains in widely-dispersed areas. We also discovered that, as a population, the emm59 epidemic isolates have accumulated relatively few genetic polymorphisms over the years since sharing a common ancestor. One hypothesis to explain this finding is that over the course of the four years represented by the emm59 strain sample used in that previous study, sufficient time has not elapsed to produce considerable genomic differentiation. Extending the genomic analysis by incorporating wholegenome data for epidemic strains more recently isolated will help to differentiate between this and other hypotheses.

Despite the ability to sequence bacterial genomes rapidly, translating the whole-genome data into insightful epidemiological findings

*Present address: Public Health Ontario, Toronto, Ontario M9P 3T1, Canada

Correspondence: JM Musser

E-mail: jmmusser@tmhs.org

Received 15 October 2012; revised 15 January 2013; accepted 7 February 2013

npg

¹Department of Pathology and Genomic Medicine, The Methodist Hospital, and Center for Molecular and Translational Human Infectious Disease Research, The Methodist Hospital Research Institute, Houston, TX 77030, USA; ²Department of Laboratory Medicine and Pathology, University of Alberta, and Provincial Laboratory for Public Health (Microbiology), Edmonton, Alberta T6G 2J2, Canada; ³Department of Laboratory Medicine and Pathobiology, University of Toronto and Department of Microbiology, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada; ⁴National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada and ⁵cBio Inc., Fremont, CA 94536, USA

Table 1 Type emm59 GAS strains incorporated in this study

ID	Strain name	Isolation date	Province	Source
1	MGAS23789	Oct-10	Alberta	Neck tissue
2	MGAS23790	Jan-10	Alberta	Blood
3	MGAS23791	Jul-11	Alberta	Bursa Lt olecranon
4	MGAS23792	Mar-11	Alberta	Knee fluid
5	MGAS23793	Jul-10	Alberta	Synovial elbow
6	MGAS23794	Feb-10	Alberta	Blood
7	MGAS23795	Apr-11	Alberta	Blood
8	MGAS23796	Mar-11	Alberta	Blood
9	MGAS23798	Mar-10	Alberta	Blood
10	MGAS23800	Aug-10	Alberta	Blood
11	MGAS23801	Apr-10	Alberta	Knee fluid
12	MGAS23802	Apr-10	Alberta	Blood
13	MGAS23803	Dec-10	Alberta	Blood
14	MGAS23805	Apr-10	Alberta	Blood
15	MGAS23806	Jul-10	Alberta	Leg Rt
16	MGAS23808	Nov-10	Alberta	Blood
17	MGAS23809	Mar-11	Alberta	Blood
18	MGAS23810	Mar-11	Alberta	Blood
19	MGAS23811	Nov-10	Alberta	Blood peripheral
20	MGAS23812	May-11	Alberta	Blood
21	MGAS23813	Feb-10	Alberta	Abscess chest wall
22	MGAS23814	Feb-11	Alberta	Blood
23	MGAS23815	Nov-10	Alberta	Blood
24	MGAS23816	Nov-10	Alberta	Tissue axilla abscess
25	MGAS23817	Jun-10	Alberta	Abscess neck
26	MGAS23818	Nov-10	Alberta	Blood
27	MGAS23819	Nov-10	Alberta	Blood
28	MGAS23787	Jan-10	British Columbia	Synovial fluid
29	MGAS23797	Dec-09	British Columbia	Blood
30	MGAS23799	Mar-10	British Columbia	Peritoneal
31	MGAS24513	Jun-10	British Columbia	Blood
32	MGAS24520	Oct-10	British Columbia	Undetermined sterile site
33	MGAS24522	Nov-10	British Columbia	Blood
34	MGAS24527	Dec-10	British Columbia	Undetermined sterile site
35	MGAS24530	Feb-11	British Columbia	Blood
36	MGAS24533	Jun-11	British Columbia	Blood
37	MGAS24535	Jul-11	British Columbia	Synovial fluid
38	MGAS24537	Aug-11	British Columbia	Blood
39	MGAS24541	Aug-11	British Columbia	Synovial fluid
40	MGAS24542	Aug-11	British Columbia	Blood
41	MGAS24509	Apr-10	Manitoba	Undetermined sterile site
42	MGAS24512	Jun-10	Manitoba	Not given
43	MGAS24525	Dec-10	Manitoba	Undetermined sterile site
44	MGAS24538	Aug-11	Manitoba	Abscess
45	MGAS24540	Aug-11	Manitoba	Synovial fluid
46	MGAS25517	Sep-10	Manitoba	Blood
47	MGAS24516	Aug-10	Northwest	Blood
			Territories	
48	MGAS24510	May-10	Nunavut	Blood
49	MGAS23788	Jan-10	Ontario	Blood
50	MGAS23804	Feb-10	Ontario	Fluid Rt knee
51	MGAS24220	Dec-93	Ontario	Undetermined sterile site
52	MGAS24223	Mar-06	Ontario	Undetermined sterile site
53	MGAS24224	Jun-06	Ontario	Undetermined sterile site
54	MGAS24225	Dec-06	Untario	Undetermined sterile site
55	MGAS24226	May-08	Ontario	Undetermined sterile site
56	MGAS24227	Uct-08	Untario	Undetermined sterile site
57	MGAS24229	Mar-09	Ontario	Undetermined sterile site
58	MGAS24230	Dec-09	Ontario	Undetermined sterile site
59	MGAS24232	Feb-10	Untario	Undetermined sterile site
60	MGAS24233	Jul-10	Ontario	Undetermined sterile site
61	MGAS24234	Aug-10	Untario	Undetermined sterile site
62	MGAS24235	Jul-10	Ontario	Undetermined sterile site
63	MGAS24236	Nov-10	Untario	Undetermined sterile site

64MGAS24237May-11OntarioUndetermined sterile site65MGAS24511May-10OntarioNot given66MGAS24514Jul-10OntarioBlood67MGAS24529Feb-11OntarioBlood68MGAS24544Sep-11OntarioBlood69MGAS24545Sep-11OntarioBlood70MGAS24547Oct-11OntarioSynovial fluid71MGAS23524Nov-10QuebecSynovial fluid72MGAS23786Jan-10QuebecBlood73MGAS23807Dec-09QuebecBlood74MGAS24507Mar-10QuebecBlood75MGAS24508Feb-10QuebecBlood76MGAS24518Oct-10QuebecBlood77MGAS24526Dec-10QuebecBlood78MGAS24528Dec-10QuebecBlood79MGAS24531Mar-11QuebecBlood80MGAS24532Mar-11QuebecBlood81MGAS24534Jun-11QuebecBlood83MGAS24543Aug-11QuebecBlood84MGAS24548Oct-11QuebecBlood85MGAS24548Oct-11QuebecBlood86MGAS24548Oct-11QuebecBlood87MGAS24548Oct-11QuebecBlood88MGAS24545Jan-10SaskatchewanBlood89	ID	Strain name	Isolation date	Province	Source
65MGAS24511May-10OntarioNot given66MGAS24514Jul-10OntarioBlood67MGAS24529Feb-11OntarioBlood68MGAS24544Sep-11OntarioBlood69MGAS24545Sep-11OntarioBlood70MGAS24547Oct-11OntarioSynovial fluid71MGAS23524Nov-10QuebecSynovial fluid72MGAS235786Jan-10QuebecBlood73MGAS23807Dec-09QuebecBlood74MGAS24507Mar-10QuebecBlood75MGAS24508Feb-10QuebecBlood76MGAS24518Oct-10QuebecBlood77MGAS24523Nov-10QuebecBlood78MGAS24524Dec-10QuebecBlood79MGAS24523Nov-10QuebecBlood80MGAS24531Mar-11QuebecBlood81MGAS24532Mar-11QuebecBlood82MGAS24534Jun-11QuebecBlood83MGAS24534Jun-11QuebecBlood84MGAS24548Oct-11QuebecBlood85MGAS24546Oct-11QuebecBlood86MGAS24548Oct-11QuebecBlood86MGAS24548Oct-11QuebecBlood87MGAS24545Jan-10SaskatchewanBlood88MGAS24546 <t< td=""><td>64</td><td>MGAS24237</td><td>May-11</td><td>Ontario</td><td>Undetermined sterile site</td></t<>	64	MGAS24237	May-11	Ontario	Undetermined sterile site
66MGAS24514Jul-10OntarioBlood67MGAS24529Feb-11OntarioBlood68MGAS24544Sep-11OntarioBlood69MGAS24545Sep-11OntarioBlood70MGAS24547Oct-11OntarioSynovial fluid71MGAS23524Nov-10QuebecSynovial fluid72MGAS23786Jan-10QuebecBlood73MGAS23807Dec-09QuebecBlood74MGAS24507Mar-10QuebecBlood75MGAS24508Feb-10QuebecBlood76MGAS24518Oct-10QuebecBlood77MGAS24526Dec-10QuebecBlood78MGAS24526Dec-10QuebecBlood79MGAS24528Dec-10QuebecBlood80MGAS24531Mar-11QuebecBlood81MGAS24532Mar-11QuebecBlood82MGAS24534Jun-11QuebecBlood83MGAS24543Aug-11QuebecBlood84MGAS24546Oct-11QuebecBlood85MGAS24548Oct-11QuebecBlood86MGAS24548Oct-11QuebecBlood87MGAS24546Oct-11QuebecBlood88MGAS24548Oct-11QuebecBlood89MGAS24515Aug-10SaskatchewanBlood89MGAS24515Aug-	65	MGAS24511	May-10	Ontario	Not given
67MGAS24529Feb-11OntarioBlood68MGAS24544Sep-11OntarioBlood69MGAS24545Sep-11OntarioBlood70MGAS24547Oct-11OntarioSynovial fluid71MGAS23524Nov-10QuebecSynovial fluid72MGAS23786Jan-10QuebecBlood73MGAS23807Dec-09QuebecBlood74MGAS24507Mar-10QuebecBlood75MGAS24508Feb-10QuebecBlood76MGAS24518Oct-10QuebecBlood77MGAS24526Dec-10QuebecBlood78MGAS24526Dec-10QuebecBlood79MGAS24528Dec-10QuebecBlood80MGAS24531Mar-11QuebecBlood81MGAS24532Mar-11QuebecBlood82MGAS24534Jun-11QuebecBlood83MGAS24543Aug-11QuebecBlood84MGAS24543Aug-11QuebecBlood85MGAS24546Oct-11QuebecBlood86MGAS24548Oct-11QuebecBlood87MGAS24546Oct-11QuebecBlood88MGAS24505Jan-10SaskatchewanBlood89MGAS24515Aug-10SaskatchewanBlood89MGAS24515Aug-10SaskatchewanBlood90MGAS24519 </td <td>66</td> <td>MGAS24514</td> <td>Jul-10</td> <td>Ontario</td> <td>Blood</td>	66	MGAS24514	Jul-10	Ontario	Blood
68MGAS24544Sep-11OntarioBlood69MGAS24545Sep-11OntarioBlood70MGAS24547Oct-11OntarioSynovial fluid71MGAS23524Nov-10QuebecSynovial fluid72MGAS23786Jan-10QuebecBlood73MGAS23807Dec-09QuebecBlood74MGAS24507Mar-10QuebecBlood75MGAS24508Feb-10QuebecBlood76MGAS24518Oct-10QuebecBlood77MGAS24526Dec-10QuebecBlood78MGAS24526Dec-10QuebecBlood79MGAS24528Dec-10QuebecBlood80MGAS24531Mar-11QuebecBlood81MGAS24532Mar-11QuebecBlood82MGAS24534Jun-11QuebecBlood83MGAS24546Aug-11QuebecBlood84MGAS24543Aug-11QuebecBlood85MGAS24546Oct-11QuebecBlood86MGAS24548Oct-11QuebecBlood87MGAS24505Jan-10SaskatchewanBlood88MGAS24515Aug-10SaskatchewanBlood89MGAS24515Aug-10SaskatchewanBlood80MGAS24519Oct-10SaskatchewanBlood	67	MGAS24529	Feb-11	Ontario	Blood
69MGAS24545Sep-11OntarioBlood70MGAS24547Oct-11OntarioSynovial fluid71MGAS23524Nov-10QuebecSynovial fluid72MGAS23786Jan-10QuebecBlood73MGAS23807Dec-09QuebecBlood74MGAS24507Mar-10QuebecBlood75MGAS24508Feb-10QuebecBlood76MGAS24518Oct-10QuebecBlood77MGAS24526Dec-10QuebecBlood78MGAS24526Dec-10QuebecBlood79MGAS24528Dec-10QuebecBlood80MGAS24531Mar-11QuebecBlood81MGAS24532Mar-11QuebecBlood82MGAS24534Jun-11QuebecBlood83MGAS24536Aug-11QuebecBlood84MGAS24543Aug-11QuebecBlood85MGAS24546Oct-11QuebecBlood86MGAS24548Oct-11QuebecBlood87MGAS24505Jan-10SaskatchewanBlood88MGAS24515Aug-10SaskatchewanBlood89MGAS24515Aug-10SaskatchewanBlood90MGAS24519Oct-10SaskatchewanBlood	68	MGAS24544	Sep-11	Ontario	Blood
70MGAS24547Oct-11OntarioSynovial fluid71MGAS23524Nov-10QuebecSynovial fluid72MGAS23786Jan-10QuebecBlood73MGAS23807Dec-09QuebecBlood74MGAS24507Mar-10QuebecBlood75MGAS24508Feb-10QuebecBlood76MGAS24518Oct-10QuebecBlood77MGAS24526Dec-10QuebecBlood78MGAS24526Dec-10QuebecBlood79MGAS24528Dec-10QuebecBlood80MGAS24531Mar-11QuebecBlood81MGAS24532Mar-11QuebecBlood82MGAS24534Jun-11QuebecBlood83MGAS24536Aug-11QuebecBlood84MGAS24543Aug-11QuebecBlood85MGAS24546Oct-11QuebecBlood86MGAS24548Oct-11QuebecBlood87MGAS24505Jan-10SaskatchewanBlood88MGAS24506Mar-10SaskatchewanBlood89MGAS24515Aug-10SaskatchewanBlood90MGAS24519Oct-10SaskatchewanBlood	69	MGAS24545	Sep-11	Ontario	Blood
71MGAS23524Nov-10QuebecSynovial fluid72MGAS23786Jan-10QuebecBlood73MGAS23807Dec-09QuebecBlood74MGAS24507Mar-10QuebecBlood75MGAS24508Feb-10QuebecBlood76MGAS24518Oct-10QuebecBlood77MGAS24523Nov-10QuebecBlood78MGAS24526Dec-10QuebecBlood79MGAS24528Dec-10QuebecBlood80MGAS24531Mar-11QuebecBlood81MGAS24532Mar-11QuebecBlood82MGAS24534Jun-11QuebecBlood83MGAS24536Aug-11QuebecBlood84MGAS24543Aug-11QuebecBlood85MGAS24546Oct-11QuebecBlood86MGAS24548Oct-11QuebecBlood87MGAS24505Jan-10SaskatchewanBlood88MGAS24515Aug-10SaskatchewanBlood89MGAS24515Aug-10SaskatchewanBlood90MGAS24519Oct-10SaskatchewanBlood	70	MGAS24547	Oct-11	Ontario	Synovial fluid
72MGAS23786Jan-10QuebecBlood73MGAS23807Dec-09QuebecBlood74MGAS24507Mar-10QuebecBlood75MGAS24508Feb-10QuebecBlood76MGAS24518Oct-10QuebecBlood77MGAS24523Nov-10QuebecBlood78MGAS24526Dec-10QuebecBlood79MGAS24528Dec-10QuebecBlood80MGAS24531Mar-11QuebecBlood81MGAS24532Mar-11QuebecBlood82MGAS24534Jun-11QuebecBlood83MGAS24536Aug-11QuebecBlood84MGAS24543Aug-11QuebecBlood85MGAS24546Oct-11QuebecBlood86MGAS24548Oct-11QuebecBlood87MGAS24505Jan-10SaskatchewanBlood88MGAS24515Aug-10SaskatchewanBlood89MGAS24515Aug-10SaskatchewanBlood90MGAS24519Oct-10SaskatchewanBlood	71	MGAS23524	Nov-10	Quebec	Synovial fluid
73MGAS23807Dec-09QuebecBlood74MGAS24507Mar-10QuebecBlood75MGAS24508Feb-10QuebecBlood76MGAS24518Oct-10QuebecBlood77MGAS24523Nov-10QuebecBlood78MGAS24526Dec-10QuebecBlood79MGAS24528Dec-10QuebecBlood80MGAS24531Mar-11QuebecBlood81MGAS24532Mar-11QuebecBlood82MGAS24534Jun-11QuebecBlood83MGAS24536Aug-11QuebecBlood84MGAS24543Aug-11QuebecBlood85MGAS24546Oct-11QuebecBlood86MGAS24548Oct-11QuebecBlood87MGAS24505Jan-10SaskatchewanBlood88MGAS24506Mar-10SaskatchewanBlood89MGAS24515Aug-10SaskatchewanBlood90MGAS24519Oct-10SaskatchewanBlood	72	MGAS23786	Jan-10	Quebec	Blood
74MGAS24507Mar-10QuebecBlood75MGAS24508Feb-10QuebecBlood76MGAS24518Oct-10QuebecBlood77MGAS24523Nov-10QuebecBlood78MGAS24526Dec-10QuebecBlood79MGAS24528Dec-10QuebecBlood80MGAS24531Mar-11QuebecBlood81MGAS24532Mar-11QuebecBlood82MGAS24534Jun-11QuebecBlood83MGAS24536Aug-11QuebecBlood84MGAS24536Aug-11QuebecBlood85MGAS24543Aug-11QuebecBlood86MGAS24546Oct-11QuebecBlood87MGAS24505Jan-10SaskatchewanBlood88MGAS24506Mar-10SaskatchewanBlood89MGAS24515Aug-10SaskatchewanBlood90MGAS24519Oct-10SaskatchewanBlood	73	MGAS23807	Dec-09	Quebec	Blood
75MGAS24508Feb-10QuebecBlood76MGAS24518Oct-10QuebecBlood77MGAS24523Nov-10QuebecBlood78MGAS24526Dec-10QuebecBlood79MGAS24528Dec-10QuebecBlood80MGAS24531Mar-11QuebecBlood81MGAS24532Mar-11QuebecBlood82MGAS24534Jun-11QuebecSynovial fluid82MGAS24536Aug-11QuebecBlood83MGAS24536Aug-11QuebecBlood84MGAS24543Aug-11QuebecBlood85MGAS24546Oct-11QuebecBlood86MGAS24548Oct-11QuebecBlood87MGAS24505Jan-10SaskatchewanBlood88MGAS24506Mar-10SaskatchewanBlood89MGAS24515Aug-10SaskatchewanBlood90MGAS24519Oct-10SaskatchewanBlood	74	MGAS24507	Mar-10	Quebec	Blood
76MGAS24518Oct-10QuebecBlood77MGAS24523Nov-10QuebecBlood78MGAS24526Dec-10QuebecBlood79MGAS24528Dec-10QuebecBlood80MGAS24531Mar-11QuebecBlood81MGAS24532Mar-11QuebecSynovial fluid82MGAS24534Jun-11QuebecUndetermined sterile site83MGAS24536Aug-11QuebecBlood84MGAS24543Aug-11QuebecBlood85MGAS24546Oct-11QuebecBlood86MGAS24548Oct-11QuebecBlood87MGAS24505Jan-10SaskatchewanBlood88MGAS24506Mar-10SaskatchewanBlood89MGAS24515Aug-10SaskatchewanBlood90MGAS24519Oct-10SaskatchewanBlood	75	MGAS24508	Feb-10	Quebec	Blood
77MGAS24523Nov-10QuebecBlood78MGAS24526Dec-10QuebecBlood79MGAS24528Dec-10QuebecBlood80MGAS24531Mar-11QuebecBlood81MGAS24532Mar-11QuebecSynovial fluid82MGAS24534Jun-11QuebecBlood83MGAS24536Aug-11QuebecBlood84MGAS24543Aug-11QuebecBlood85MGAS24546Oct-11QuebecBlood86MGAS24548Oct-11QuebecBlood87MGAS24505Jan-10SaskatchewanBlood88MGAS24515Aug-10SaskatchewanBlood89MGAS24515Aug-10SaskatchewanBlood90MGAS24519Oct-10SaskatchewanBlood	76	MGAS24518	Oct-10	Quebec	Blood
78MGAS24526Dec-10QuebecBlood79MGAS24528Dec-10QuebecBlood80MGAS24531Mar-11QuebecBlood81MGAS24532Mar-11QuebecSynovial fluid82MGAS24534Jun-11QuebecUndetermined sterile site83MGAS24536Aug-11QuebecBlood84MGAS24543Aug-11QuebecBlood85MGAS24546Oct-11QuebecBlood86MGAS24548Oct-11QuebecBlood87MGAS24505Jan-10SaskatchewanBlood88MGAS24506Mar-10SaskatchewanBlood89MGAS24515Aug-10SaskatchewanBlood90MGAS24519Oct-10SaskatchewanBlood	77	MGAS24523	Nov-10	Quebec	Blood
79MGAS24528Dec-10QuebecBlood80MGAS24531Mar-11QuebecBlood81MGAS24532Mar-11QuebecSynovial fluid82MGAS24534Jun-11QuebecUndetermined sterile site83MGAS24536Aug-11QuebecBlood84MGAS24543Aug-11QuebecBlood85MGAS24546Oct-11QuebecBlood86MGAS24548Oct-11QuebecBlood87MGAS24505Jan-10SaskatchewanBlood88MGAS24506Mar-10SaskatchewanBlood89MGAS24515Aug-10SaskatchewanBlood90MGAS24519Oct-10SaskatchewanBlood	78	MGAS24526	Dec-10	Quebec	Blood
80MGAS24531Mar-11QuebecBlood81MGAS24532Mar-11QuebecSynovial fluid82MGAS24534Jun-11QuebecUndetermined sterile site83MGAS24536Aug-11QuebecBlood84MGAS24543Aug-11QuebecSynovial fluid85MGAS24546Oct-11QuebecBlood86MGAS24548Oct-11QuebecBlood87MGAS24505Jan-10SaskatchewanBlood88MGAS24506Mar-10SaskatchewanBlood89MGAS24515Aug-10SaskatchewanBlood90MGAS24519Oct-10SaskatchewanBlood	79	MGAS24528	Dec-10	Quebec	Blood
81MGAS24532Mar-11QuebecSynovial fluid82MGAS24534Jun-11QuebecUndetermined sterile site83MGAS24536Aug-11QuebecBlood84MGAS24543Aug-11QuebecSynovial fluid85MGAS24546Oct-11QuebecBlood86MGAS24548Oct-11QuebecBlood87MGAS24505Jan-10SaskatchewanBlood88MGAS24506Mar-10SaskatchewanBlood89MGAS24515Aug-10SaskatchewanBlood90MGAS24519Oct-10SaskatchewanBlood	80	MGAS24531	Mar-11	Quebec	Blood
82MGAS24534Jun-11QuebecUndetermined sterile site83MGAS24536Aug-11QuebecBlood84MGAS24543Aug-11QuebecSynovial fluid85MGAS24546Oct-11QuebecBlood86MGAS24548Oct-11QuebecBlood87MGAS24505Jan-10SaskatchewanBlood88MGAS24506Mar-10SaskatchewanBlood89MGAS24515Aug-10SaskatchewanBlood90MGAS24519Oct-10SaskatchewanBlood	81	MGAS24532	Mar-11	Quebec	Synovial fluid
83MGAS24536Aug-11QuebecBlood84MGAS24543Aug-11QuebecSynovial fluid85MGAS24546Oct-11QuebecBlood86MGAS24548Oct-11QuebecBlood87MGAS24505Jan-10SaskatchewanBlood88MGAS24506Mar-10SaskatchewanBlood89MGAS24515Aug-10SaskatchewanBlood90MGAS24519Oct-10SaskatchewanBlood	82	MGAS24534	Jun-11	Quebec	Undetermined sterile site
84MGAS24543Aug-11QuebecSynovial fluid85MGAS24546Oct-11QuebecBlood86MGAS24548Oct-11QuebecBlood87MGAS24505Jan-10SaskatchewanBlood88MGAS24506Mar-10SaskatchewanBlood89MGAS24515Aug-10SaskatchewanBlood90MGAS24519Oct-10SaskatchewanBlood	83	MGAS24536	Aug-11	Quebec	Blood
85MGAS24546Oct-11QuebecBlood86MGAS24548Oct-11QuebecBlood87MGAS24505Jan-10SaskatchewanBlood88MGAS24506Mar-10SaskatchewanBlood89MGAS24515Aug-10SaskatchewanBlood90MGAS24519Oct-10SaskatchewanBlood	84	MGAS24543	Aug-11	Quebec	Synovial fluid
86MGAS24548Oct-11QuebecBlood87MGAS24505Jan-10SaskatchewanBlood88MGAS24506Mar-10SaskatchewanBlood89MGAS24515Aug-10SaskatchewanBlood90MGAS24519Oct-10SaskatchewanBlood	85	MGAS24546	Oct-11	Quebec	Blood
87MGAS24505Jan-10SaskatchewanBlood88MGAS24506Mar-10SaskatchewanBlood89MGAS24515Aug-10SaskatchewanBlood90MGAS24519Oct-10SaskatchewanBlood	86	MGAS24548	Oct-11	Quebec	Blood
88MGAS24506Mar-10SaskatchewanBlood89MGAS24515Aug-10SaskatchewanBlood90MGAS24519Oct-10SaskatchewanBlood	87	MGAS24505	Jan-10	Saskatchewan	Blood
89MGAS24515Aug-10SaskatchewanBlood90MGAS24519Oct-10SaskatchewanBlood	88	MGAS24506	Mar-10	Saskatchewan	Blood
90 MGAS24519 Oct-10 Saskatchewan Blood	89	MGAS24515	Aug-10	Saskatchewan	Blood
	90	MGAS24519	Oct-10	Saskatchewan	Blood

Abbreviations: Lt, left; Rt, right.

Table 1 Continued

remains relatively time consuming and requires intensive logistical and computing resources.¹³ In addition, incorporating critical strain or patient metadata into the analysis, and displaying the data in a more visual, intuitive and integrative fashion is challenging. Collectively, these problems hinder the clinical and public health responses to natural and accidental outbreaks, and deliberate release of infectious agents. Thus, methods to rapidly translate genome data into accurate, epidemiologically relevant information in a short period of time are needed. Here, we have attempted to address these limitations by use of whole-genome data from additional strains recovered from the ongoing *emm59* GAS epidemic. Whole-genome data for 90 additional *emm59* GAS strains isolated in Canada were generated and integrated into an improved pipeline for data processing and visualization. We show here that pertinent epidemiological information can be obtained rapidly and economically in meaningful clinical and public health situations.

MATERIALS AND METHODS

Bacterial strains

The strain collection includes 691 *emm59* strains of different origins. 601 of these strains have been described in detail recently.⁸ The additional 90 strains (Table 1) were all isolated in Canada from patients with invasive GAS infections. One of these strains was isolated in 1993 in Ontario, and is thus far the oldest identified Canadian *emm59* GAS organism. Nine strains were isolated during 2006–2009, the period of time covered by our previous report on the *emm59* epidemic,⁸ but had not been included in the previous study. The vast majority (*n*=80) of the newly analyzed strains were isolated in 2010 and 2011.

Whole-genome sequencing

DNA was extracted from each of the 90 *emm59* GAS isolates and prepared for multiplexed (barcoded) sequencing as previously

Whole-genome investigation of a GAS epidemic N Fittipaldi *et al*

described.⁹ Genome sequence data were obtained using an Illumina HiSeq2000 instrument according to the manufacturer's instructions.

Bioinformatic analysis

Bioinformatic analysis was performed using a customized version of the Galaxy Suite²⁰⁻²² running on the Amazon cloud. Namely, we created a pipeline composed of Tagdust,²³ FastQC (http://www. bioinformatics.bbsrc.ac.uk/projects/fastqc/) and FastX (http://hannonlab. cshl.edu/fastx toolkit/) toolkits, and used it to parse multiplexed sequencing reads, remove barcode information and perform run quality control analyses. Polymorphism discovery was performed using Variant Ascertainment Algorithm.²⁴ Reads were aligned to the emm59 GAS strain MGAS15252 (GenBank accession number CP003116) reference genome using the Mosaik assembler (http://bioinformatics.bc.edu/marthlab/ Mosaik). This strain was isolated in Canada in 2008 and its genome sequenced to closure previously; thus becoming the de facto reference genome for type emm59 GAS epidemic strains.8 Unaligned reads were placed into contigs using the Velvet *de novo* assembler.²⁵ Contigs greater than 100 nucleotides in length were then used to search the NCBI nonredundant database using BLAST.26

Phylogenetic analysis

A matrix file containing the genotype of all strains at each polymorphic locus was created from the Variant Ascertainment Algorithm polymorphism output data using a custom script. Insertions and deletions (indels) were not considered for phylogenetic analysis. Single-nucleotide polymorphisms (SNPs) were concatenated in order of occurrence relative to the reference genome and converted to a multiFASTA sequence. ClustalW²⁷ was used to align and generate a guide tree for the FASTA sequences. Neighbor-joining phylogenetic trees followed by bootstrap analysis of 1000 replicates were created using SplitsTree²⁸ and graphically edited with TreeDyn.²⁹ The Neighbor-joining phylogenetic tree for Canadian epidemic strains isolated 2006–2011 was exported to Path-O-Gen v1.3 (http://tree.bio.ed.ac.uk/software/pathogen) and a linear regression plot for isolation date versus root-to-tip distance was generated as described by Mutreja *et al.*³⁰

Data visualizations

Visualizations were created using the resources offered by cBio Inc.'s Pathogen Annotated Tracking Resource Network located at http:// www.patrn.net/. Illustrations were created using TIBCO Spotfire and Adobe Illustrator.

RESULTS

Invasive infections caused by *emm59* GAS remain abundant in Canada

We reported previously that *emm59* GAS strains were almost nonexistent in Canada before 2006, but caused more than 500 invasive infections countrywide from that date until early 2010.^{8,18} The epidemic reached its peak in 2008, after which the number of cases began to decline (Figure 1A). However, *emm59* GAS strains continued to cause invasive infections, with 56 newly identified cases in 2010 (total of 70 cases for 2010), and 32 cases in 2011. Since surveillance for GAS is passive in Canada, the actual number of *emm59* GAS invasive cases is likely to have been higher in the period under investigation. During



Figure 1 Number of *emm59* GAS recorded cases in Canada and their geographic distribution since the beginning of the epidemic. (A) The epidemic began in year 2006 and reached its peak in 2008. By that year, cases of invasive disease were recorded over the vast majority of the country. The number of cases started to decline since 2009. However, in years 2010 and 2011, strains could still be recovered in relatively large numbers. (B) Temporospatial display of strain origin. Provinces in which *emm59* GAS strains were isolated are color coded based on the number of strain isolated each year. Numbers indicate the exact number of strains isolated in a particular year in each province.

2010 and 2011, cases occurred in vastly dispersed geographical areas covering most of the country (Figure 1B).

The oldest Canadian *emm59* GAS strain identified is not the immediate ancestor of the epidemic *emm59* clone

Our previous genome investigation of *emm59* GAS strains recovered in Canada unambiguously demonstrated that regardless of geographic location or year of isolation, epidemic Canadian *emm59* strains have descended from a recent, single ancestral cell that underwent rapid geographic dissemination.⁸ The last common ancestor remains unidentified, but it was remarkable that the genomes of the epidemic strains and those of the only seven *emm59* strains isolated in Canada before the epidemic began (1997–2004) were closely related.⁸ We sequenced here the genome of an *emm59* strain isolated in Canada in 1993, thus far the oldest Canadian *emm59* organism identified. The genome sequence data show that this strain is genetically distantly related to the epidemic strains and thus is not the recent ancestor. Indeed, compared to reference epidemic strain MGAS15252, the 1993 *emm59* GAS strain had 194 SNPs and 20 indels in the core genome (i.e., the ~1670 kbp portion of the genome lacking mobile genetic elements that is conserved in gene content across all sequenced *emm* GAS types³¹). Phylogenetic analysis using SNP data for the core genomes found that this historic Canadian isolate also is not closely related to non-epidemic *emm59* GAS organisms isolated in other geographic locations such as the United States, Japan or Spain (Figure 2A).

Comparative genome sequencing of new Canadian epidemic *emm59* strains

The 89 additional *emm59* GAS Canadian organisms differed from the reference strain, on average, by 10 SNPs and 3.4 indels (median 12



Figure 2 (A) Inferred genetic relationships among strains based on 1443 concatenated SNP loci identified by whole-genome sequencing. Newly sequenced strains all cluster within the epidemic clonal complex, with the exception of a Canadian *emm59* GAS strain isolated in 1993. This strain is also genetically distant from invasive strains from Spain, Japan and the United States. Scale bar represents genetic distance. (B) Magnification of the epidemic complex part of the tree, showing the geographical area of isolation (Canadian province or US state). Strains recovered during years 2010–2011 are highlighted. In general, these more recent strains are found in the outermost part of every tree branch.

SNPs, 3 indels). The notable exception was strain MGAS24525, isolated in Manitoba in 2010, which had 465 SNPs and 71 indels relative to the reference strain. However, the vast majority of these polymorphisms mapped to mobile genetic elements, namely, prophages present in the reference sequence. Indeed, compared with the core genome of the reference strain, the number of polymorphisms was reduced to only 30 SNPs and 5 indels. Moreover, 15 of these 30 SNPs mapped to sequences in close vicinity of prophage boundaries. These results suggest that strain MGAS24525 is a *bona fide emm59* GAS epidemic strain that has very recently acquired a different prophage. Phylogenetic analysis using the whole-genome data showed that the Canadian *emm59* GAS organisms clustered tightly in the epidemic complex (Figure 2A).

Epidemic Canadian *emm59* GAS strains continue to undergo clonal expansion

One of the findings of our previous work was that, as a population, the emm59 epidemic isolates have accumulated relatively few genetic polymorphisms over the years since sharing a last common ancestor. One hypothesis to explain that finding is that over the course of the 4 vears represented by the emm59 strains used in the previous study. sufficient time has not elapsed to produce considerable genomic differentiation. Adding to the analysis data for 80 additional strains isolated in 2010-2011 provided us with the ability to test the hypothesis over a period of time of almost 6 years. Phylogenetic analysis of strains isolated during 2010-2011 found that these recent strains were located, in general, toward the tip of multiple branches of the phylogenetic tree, implying that they have accumulated additional SNPs compared to emm59 GAS organisms isolated previously (Figure 2B). When we divided the strain collection based on isolation year and calculated the average number of SNPs separating the epidemic strains isolated in a given year from the reference strain, we noticed an increase in the number of polymorphisms differentiating the epidemic strains from the reference strain over time. For example, epidemic strains recovered in 2006 differed from the reference genome, on average, by 7.6 SNPs, whereas strains isolated in 2011 differed, on average, by 13.1 SNPs. To test the hypothesis in more detail, we performed a linear regression analysis on all epidemic strains isolated since 2006 to calculate the rate of SNP accumulation on the basis of the date of isolation and the root-to-tip distance. Consistent with the hypothesis, linear regression analysis showed a steady rate of SNP accumulation (R^2 =0.6067; Figure 3) in the core genome.

Use of whole-genome data to study temporospatial spread of *emm59* GAS subclones

Among the critical questions that whole-genome sequencing and subsequent phylogenetic analyses can address is whether an apparent epidemic represents the emergence of a single distinct genotype, or, instead, it is caused by multiple clones that emerged simultaneously. In our initial investigation, we unambiguously demonstrated the emm59 GAS epidemic was caused by the emergence of a distinct genetic clone.8 The extensive whole-genome data also permitted us to delineate clear patterns of geographic dissemination of derivative subclones.8 We inferred that these geographic patterns were the result of the rapid spread of subclones in distinct geographic regions of the country. We hypothesized that the geographical patterns will begin to be obscured over time as a result of geographic mixing of subclones linked to human travel. Figure 4A clearly exemplifies how whole-genome data support this hypothesis: a subclone that before 2009 was composed only of strains isolated in the provinces of Alberta and British Columbia has expanded to four other Canadian provinces



Figure 3 Linear regression plot showing the correlation (R^2) between the root-totip distance (*y*-axis) and the date of the epidemic strains (*x*-axis).

and territories. Mixing of the subclones is also clearly revealed among strains isolated in Quebec. Type emm59 GAS had been isolated in Quebec in 1996 and 2004, particularly in northern areas of the province. Quebec interrupted the provincial GAS surveillance program during 2005-2009. We discovered that none of the 28 emm59 GAS invasive cases reported in the province since 2009 was caused by direct lineal descendants of the strains originally identified in Quebec. Rather, they were caused by strains of genetically divergent emm59 subclones isolated first in other parts of Canada and subsequently introduced into the province on at least four different occasions (Figure 4B and 4C). Notably, we identified five strains whose genomes were essentially identical. Four of these strains were isolated from patients receiving care in the Montreal area, whereas the fifth was from a patient in Ontario. This is incontrovertible evidence that the strains have shared a very recent common ancestor and, also, most likely represents that the patients infected by these strains were connected to one another, either directly or via an unknown third-party donor. Temporal analysis revealed that the Ontario case was the last to be isolated (Figure 4D), indicating a reversal of the west to east route of transmission identified in our previous study.⁸

Convergent evolution of polymorphisms in virulence genes

The radial structure of the epidemic phylogenetic tree (Figure 2B) suggested that most of the SNPs identified in our strain collection arose once and were transmitted vertically by descent. Polymorphisms that arise independently multiple times are of interest since they may represent genetic changes that are under evolutionary selection because they confer an advantage to the organism. We identified several examples of these polymorphisms, including a single nucleotide deletion in a homopolymeric tract of 7 Ts, predicted to result in premature termination of translation of CovS,



Figure 4 (A) Geographic patterns of strains dissemination are diluted as the epidemic progresses over time. The highlighted areas of the tree exemplifies how specific subclones, previously restricted to specific geographical areas of Canada before 2009, are now found over vast regions of the country. Triangles represent *emm59* GAS strains not considered for the analysis. (B) Epidemic strains isolated in the province of Quebec since 2009 were introduced into the province in at least five different occasions. Strains from Quebec are depicted in blue and their different locations in the phylogenetic tree highlighted by the black ellipses. With the exception of a 'native' population of strains isolated before 2006, all cases in the province were the result of the introduction of multiple different *emm59* GAS subclones active in other parts of Canada. (C) Introduction of the different genotypes into Quebec can be precisely mapped back to the origin strain. (D) Magnification of a region of the phylogenetic depicting a subclone composed of five strains of identical genome sequence which caused disease in the Montreal area, but was later isolated in the province of Ontario.



Figure 5 Different polymorphisms arose multiple, independent times. Polymorphism analysis identified that several strains in different branches of the phylogenetic tree present either a nucleotide deletion (del T83) resulting in premature termination of the translation of the global regulator *covS* (indicated in red) and/or a SNP (A601C) resulting in a nonsynonymous amino acid replacement (His201Arg) in the stand alone regulator Mga (indicated in light blue). These polymorphisms could not have been inherited by descent. Their multiple, independent acquisition within the host suggests that they confer a selective advantage.

the sensor kinase of the two-component regulatory system CovRS. This component regulatory system influences the expression of a large regulon that includes many virulence genes.³² CovR acts primarily as a transcriptional repressor of virulence genes. Inactivation of *covR* or *covS* has been reported to increase GAS virulence in strains of several different *emm* types.³² The distribution of this deletion-mutation strongly suggests that it evolved independently on least six different occasions in *emm59* GAS strains (Figure 5). We also identified multiple different non-synonymous SNPs in the *mga* gene which encodes a stand alone global regulator of GAS virulence. Mga is important at several steps of the pathogenesis of the GAS infection, and is required for full GAS virulence in a skin model of infection.^{33,34} The phylogenetic distribution of one of these SNPs (resulting in a His201Arg amino-acid replacement) strongly suggests that it arose independently at least six times (Figure 5).

DISCUSSION

Our study supports the idea that performing whole-genome sequencing and data interpretation rapidly can have a major impact on the study and management of epidemics. New and improved sequencing systems permit genome sequence data to be generated economically for hundreds of strains in as little as a week. A time frame as short as 1.5 days has been reported for obtaining high-quality genome data for a small number of strains.³⁵ However, data analysis continues to be a key bottleneck in genome sequence-based investigations.

During an epidemic, irrespective of whether it is natural or caused by the accidental or deliberate release of a pathogenic organism, there is substantial pressure to obtain high-quality genome and linked epidemiologic information very rapidly. It is therefore important to identify exactly what is being traced at as high resolution as possible. Important questions to be addressed are: Is this a clonal outbreak or are several pathogen genetic backgrounds involved? What is the nature and extent of organism evolution during the course of the epidemic? Here, using an improved data analysis pipeline, we have been able to accurately identify polymorphisms for 90 strains in less than 24 h after obtaining the raw data from the sequencing instrument. As importantly, we were able to integrate new and preexisting data along with geographical and temporal strain metadata to rapidly generate phylogenetic trees and other visualizations that translated the data into intuitive and insightful epidemiological information. By applying this analysis, we were able to differentiate among emm59 GAS subclones causing disease in different and geographically dispersed parts of Canada, and obtain new information about how these clones are expanding and mixing over time.

Two other important issues when studying an epidemic are identifying the origin of the organism(s) causing it and the ability to exclude or confirm genetic modifications. By limiting our analysis to the province of Quebec, we demonstrated that whole-genome sequencing, phylogenetic and temporospatial analysis were able to assign the different cases reported in the province to at least five different subclones of *emm59* GAS. Moreover, we unambiguously demonstrated transmission of a particular subclone which has been active for months in the Montreal area to the province of Ontario. This type of crucial information is important for providing input on public health maneuvers, for understanding strain spreading and for inferring whether an epidemic is naturally caused or potentially the result of deliberate release of a pathogenic organism.

Whole-genome sequencing of large numbers of strains causing epidemics has also proven useful to characterize many biological properties of the organisms under investigation and is revolutionizing both virulence factor discovery and characterization and our under-standing of bacterial pathogenesis.^{36–38} In our analysis of the *emm59* GAS epidemic in Canada, we rapidly identified several polymorphisms that arose multiple, independent times in the strains studied. Among others, we discovered such polymorphisms in global regulators of GAS virulence, such as a nucleotide deletion in the covS gene and a SNP resulting in a non-synonymous amino-acid change at position 201 of the predicted translated sequence of the standalone regulator Mga. Selection within the host of these polymorphisms may denote that they are of importance for the pathogenesis of infection. Although evaluating the potential involvement of these naturally occurring polymorphisms in GAS virulence requires further time and effort, it is worth noting that whole-genome sequencing analysis can lead to the quick generation of research hypothesis bearing on pathogenesis even during the initial analysis of epidemics.

In this study, we limited our analysis to genome data and temporospatial isolation information for bacterial strains. It would be possible, however, to rapidly build a well-curated database integrating other metadata such as, for example, disease manifestation and patient information, including patient genome data. Such efforts are currently underway in some clinical settings.¹³ Whole-genome sequencing and integrative metadata analysis holds the promise of monitoring the spread and evolution of pathogens in real time, facilitating management of disease and patient treatment and continuing to provide leads for future research aimed at deciphering the virulence arsenal of pathogenic bacteria. The strategy we used here is a step forward in the route toward automation of whole-genome sequencing data analysis and provides a framework upon which to build more intuitive, rapid and precise analytic tools.

ACKNOWLEDGMENTS

We thank the following hospitals or provincial public health laboratories for contributing GAS isolates to this study: British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada; Saskatchewan Disease Control Laboratory, Regina, Saskatchewan, Canada; Cadham Provincial Laboratory, Winnipeg, Manitoba, Canada; Public Health Ontario Laboratories, Toronto, Ontario, Canada; Laboratoire de santé publique du Québec, Ste-Anne-de-Bellevue, Quebec, Canada; Stanton Territorial Hospital Laboratory, Yellowknife, Northwest Territories, Canada. We thank Concepcion C. Cantu from the Methodist Hospital Research Institute for technical help. This work was supported by The Methodist Hospital. Nahuel Fittipaldi is funded in part by a Postdoctoral Fellowship granted by the Canadian Institutes of Health Research, Ottawa, Ontario, Canada.

- Dasgupta A, Banerjee R, Das S, Basak S. Evolutionary perspective on the origin of Haitian cholera outbreak strain. J Biomol Struct Dyn 2012; 30: 338–346.
- 2 Chin CS, Sorenson J, Harris JB et al. The origin of the Haitian cholera outbreak strain. N Engl J Med 2011; 364: 33–42.
- 3 Gardy JL, Johnston JC, Ho Sui SJ et al. Whole-genome sequencing and social-network analysis of a tuberculosis outbreak. N Engl J Med 2011; 364: 730–739.
- 4 Gilmour MW, Graham M, van Domselaar G et al. High-throughput genome sequencing of two Listeria monocytogenes clinical isolates during a large foodborne outbreak. BMC Genomics 2010; 11: 120.
- 5 Rasko DA, Webster DR, Sahl JW et al. Origins of the E. colistrain causing an outbreak of hemolytic-uremic syndrome in Germany. N Engl J Med 2011; 365: 709–717.

- 6 Rohde H, Qin J, Cui Y et al. Open-source genomic analysis of Shiga-toxin-producing E. coli 0104:H4. N Engl J Med 2011; 365: 718–724.
- 7 Beres SB, Carroll RK, Shea PR et al. Molecular complexity of successive bacterial epidemics deconvoluted by comparative pathogenomics. Proc Natl Acad Sci USA 2010; 107: 4371–4376.
- 8 Fittipaldi N, Beres SB, Olsen RJ et al. Full-genome dissection of an epidemic of severe invasive disease caused by a hypervirulent, recently emerged clone of group A Streptococcus. Am J Pathol 2012; 180: 1522–1534.
- 9 Shea PR, Beres SB, Flores AR et al. Distinct signatures of diversifying selection revealed by genome analysis of respiratory tract and invasive bacterial populations. Proc Natl Acad Sci USA 2011; 108: 5039–5044.
- 10 Loman NJ, Constantinidou C, Chan JZ *et al.* High-throughput bacterial genome sequencing: an embarrassment of choice, a world of opportunity. *Nat Rev Microbiol* 2012; **10**: 599–606.
- 11 Otto TD. Real-time sequencing. Nat Rev Microbiol 2011; 9: 633.
- 12 Baldry S. Attack of the clones. *Nat Rev Microbiol* 2010; **8**: 390.
- 13 Olsen RJ, Long SW, Musser JM. Bacterial genomics in infectious disease and the clinical pathology laboratory. Arch Pathol Lab Med 2012; 136: 1414–1422.
- 14 Olsen RJ, Shelburne SA, Musser JM. Molecular mechanisms underlying group A streptococcal pathogenesis. *Cell Microbiol* 2009; **11**: 1–12.
- 15 Lancefield RC. The antigenic complex of *Streptococcus haemolyticus*: I. Demonstration of a type-specific substance in extracts of *Streptococcus haemolyticus*. J Exp Med 1928; 47: 91–103.
- 16 Scott JR, Pulliam WM, Hollingshead SK, Fischetti VA. Relationship of M protein genes in group A streptococci. Proc Natl Acad Sci USA 1985; 82: 1822–1826.
- 17 Manjula BN, Acharya AS, Fairwell T, Fischetti VA. Antigenic domains of the streptococcal Pep M5 protein. Localization of epitopes crossreactive with type 6 M protein and identification of a hypervariable region of the M molecule. J Exp Med 1986; 163: 129–138.
- 18 Tyrrell GJ, Lovgren M, St Jean T et al. Epidemic of group A Streptococcus M/emm59 causing invasive disease in Canada. Clin Infect Dis 2010; 51: 1290–1297.
- 19 Fittipaldi N, Olsen RJ, Beres SB, van Beneden C, Musser JM. Genomic analysis of emm59 group A Streptococcus invasive strains, United States. Emerg Infect Dis 2012; 18: 650–652.
- 20 Blankenberg D, von Kuster G, Coraor N et al. Galaxy: a web-based genome analysis tool for experimentalists. Curr Protoc Mol Biol 2010; Chapter 19: Unit 19.10.1–21.
- 21 Giardine B, Riemer C, Hardison RC et al. Galaxy: a platform for interactive large-scale genome analysis. Genome Res 2005; 15: 1451–1455.
- 22 Goecks J, Nekrutenko A, Taylor J. Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences. *Genome Biol* 2010; 11: R86.
- 23 Lassmann T, Hayashizaki Y, Daub CO. TagDust—a program to eliminate artifacts from next generation sequencing data. *Bioinformatics* 2009; 25: 2839–2840.
- 24 Nusbaum C, Ohsumi TK, Gomez J *et al.* Sensitive, specific polymorphism discovery in bacteria using massively parallel sequencing. *Nat Methods* 2009; 6: 67–69.
- 25 Zerbino DR, Birney E. Velvet: algorithms for *de novo* short read assembly using de Bruijn graphs. *Genome Res* 2008; **18**: 821–829.
- 26 Altschul SF, Madden TL, Schaffer AA et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997; 25: 3389–3402.
- 27 Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. *Nucleic Acids Res* 1994; 22: 4673–4680.
- 28 Huson DH, Bryant D. Application of phylogenetic networks in evolutionary studies. Mol Biol Evol 2006; 23: 254–267.
- 29 Chevenet F, Brun C, Banuls AL, Jacq B, Christen R. TreeDyn: towards dynamic graphics and annotations for analyses of trees. *BMC Bioinformatics* 2006; 7: 439.
- 30 Mutreja A, Kim DW, Thomson NR et al. Evidence for several waves of global transmission in the seventh cholera pandemic. Nature 2011; 477: 462–465.
- 31 Beres SB, Musser JM. Contribution of exogenous genetic elements to the group A Streptococcus metagenome. PLoS ONE 2007; 2: e800.
- 32 Churchward G. The two faces of Janus: virulence gene regulation by CovR/S in group A streptococci. Mol Microbiol 2007; 64: 34–41.
- 33 Luo F, Lizano S, Banik S, Zhang H, Bessen DE. Role of Mga in group A streptococcal infection at the skin epithelium. *Microb Pathog* 2008; 45: 217–224.
- 34 Hondorp ER, McIver KS. The Mga virulence regulon: infection where the grass is greener. *Mol Microbiol* 2007; 66: 1056–1065.
- 35 Koser CU, Holden MT, Ellington MJ et al. Rapid whole-genome sequencing for investigation of a neonatal MRSA outbreak. N Engl J Med 2012; 366: 2267–2275.
- 36 Georgiades K. Genomics of epidemic pathogens. Clin Microbiol Infect 2012; 18: 213–217.
- 37 Dettman JR, Rodrigue N, Melnyk AH, Wong A, Bailey SF, Kassen R. Evolutionary insight from whole-genome sequencing of experimentally evolved microbes. *Mol Ecol* 2012; 21: 2058–2077.
- 38 Musser JM, Shelburne SA 3rd. A decade of molecular pathogenomic analysis of group A Streptococcus. J Clin Invest 2009; 119: 2455–2463.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivative Works 3.0 Unported License. To view a copy of this license, visit http:// creativecommons.org/licenses/by-nc-nd/3.0